PRINCETON, N.J., Nov. 18, 2011 /PRNewswire/ -- Kremers Urban Pharmaceuticals Inc. today announced that it has entered into a settlement agreement which will resolve litigation related to Lipitor® Tablets, 10 mg, 20 mg, 40 mg, and 80 mg, known generically as Atorvastatin Calcium tablets.
The terms of the agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.
About Kremers Urban
Kremers Urban Pharmaceuticals Inc., a specialty generic drug manufacturer and subsidiary of Belgium-based UCB, is a pioneer in developing generic versions of pharmaceutical products that have a “high barrier to entry.” The Company is moving to the forefront of delivering the tough solutions necessary to get complex products into the market. To learn more visit www.kremersurban.com.
For More Information Contact:
France Nivelle, Global Communications
+32 2 559 9178; france.nivelle@ucb.com
Antje Witte, Investor Relations
+32 2 559 9414; antje.witte@ucb.com
SOURCE Kremers Urban Pharmaceuticals Inc.
